Shares in Tandem Diabetes Care (NSDQ:TNDM) rose yesterday after the insulin pump maker beat expectations on Wall Street with its fourth quarter and full-year results. The San Diego Calif.-based company reeled in its losses in Q4, posting a net loss of -$11.4 million on sales of $40.3 million for the 3 months ended Dec. 31, for […]
Tandem Diabetes Care
Tandem Diabetes bids for Health Canada nod
Tandem Diabetes Care (NSDQ:TNDM) has submitted a medical device license application to Health Canada in the hopes of launching its t:slim X2 insulin pump in Canada in the second half of this year. The San Diego, Calif.-based company expects that its device will be able to display both English and French and will include a 24-hour […]
Tandem inks distribution deal in Scandinavia for insulin pumps
Tandem Diabetes Care (NSDQ:TNDM) has inked a distribution agreement with Rubin Medical to commercialize the medical device company’s t:slim X2 insulin pump, insulin cartridges and t:lock infusion sets in Sweden, Norway and Denmark. According to the terms of the deal, Rubin Medical is slated to perform all sales, marketing and customer training for Tandem’s devices. “This represents […]
Tandem Diabetes touts pivotal study of insulin pump with low glucose suspend feature
Tandem Diabetes Care (NSDQ:TNDM) touted data today from a pivotal study of its t:slim X2 insulin pump, which features a predictive low glucose suspend feature called Basal-IQ. The study showed that the system reduced time spent in hypoglycemia by 31% compared to just sensor-augmented pump therapy, according to Tandem. Tandem’s t:slim pump uses data from Dexcom’s G5 […]
Tandem closes $69m underwritten public offering
Tandem Diabetes Care (NSDQ:TNDM) has closed its previously-announced underwritten public offering of 30 million shares of common stock at $2.00 apiece. The San Diego, Calif.-based company reeled in $69 million from the offering, after underwriters exercised an option to buy 4.5 million additional shares of Tandem’s common stock. The insulin pump-maker has tried to drum up […]
Tandem Diabetes Care prices $60m offering
Tandem Diabetes Care (NSDQ:TNDM) has priced an underwritten public offering of 30 million shares of common stock at $2.00 apiece. The San Diego, Calif.-based company said it expects to reel in $60 million from the offering. Tandem also gave underwriters a 30-day option to buy up to 4.5 million more shares of common stock. The offering […]
Tandem Diabetes registers $40m offering
Tandem Diabetes Care (NSDQ:TNDM) has registered for a $40 million offering of its common stock, according to an SEC filing posted today. Shareholders for the San Deigo, Calif.-based company approved a proposal last year to effect a 1-for-10 reverse stock split that they believed would help make Tandem’s stock more attractive to institutional investors. “Our board […]
Tandem Diabetes Care launches manufacturing ops at new San Diego plant
Tandem Diabetes Care (NSDQ:TNDM) said today that its new San Diego, Calif.-based manufacturing facility is fully operational. The 50,000 square foot plant doubles the company’s previous manufacturing capacity for insulin pumps and cartridges, Tandem reported, and expands its available warehousing for infusion set supplies. Tandem’s new facility has two insulin pump production lines, four cartridge manufacturing […]
Tandem’s finance chief to retire at year’s end | Personnel Moves – Dec. 8, 2017
Tandem Diabetes Care (NSDQ:TNDM) announced today that its EVP and chief financial exec, John Cajigas, will retire at the end of 2017. The company’s SVP of finance, Leigh Vosseller, is slated to take his place effective Jan. 1. Tandem noted that Cajigas’ retirement is not due to any disagreement or problem with the company’s accounting or […]
Tandem reels in losses but misses revenue estimates in Q3
Shares in Tandem Diabetes Care (NSDQ:TNDM) rose today after the medical device maker reeled in its losses but missed sales estimates on Wall Street with its third quarter results. The San Diego, Calif.-based company posted losses of -$16 million on sales of $23.7 million for the 3 months ended Sept. 30, for bottom-line growth of 46% […]
